TABLE 3.

ROR₀₂₅ values between class‐specific ICIs monotherapy/polytherapy (without chemotherapy) and the top 10 most frequently reported renal AEs in FAERS database

PT	Nivo	Pemb	Cemi	Atez	Avel	Durv	Ipil	Poly2	Poly3
Acute kidney injury	1.66	1.28	0.97	3.47	0.66	2.19	1.04	3.19	1.70
Renal failure	0.68	0.48		0.76	0.80		0.11	0.57
Renal impairment	1.06	1.18		0.69			0.49	0.33
Urinary tract infection	0.34	0.21		0.63			0.10	0.48
Tubulointerstitial nephritis	0.80	1.31		0.92			0.59	1.38
Chronic kidney disease	0.27	0.15		0.40		0.33	0.26	0.10
Nephritis	8.94	15.15		12.68			1.47	11.20
Hematuria	0.81	0.70		3.09			0.43	0.56
Urinary retention	0.65	0.51		0.90			0.18	0.19
Chromaturia	0.67	0.65					1.24	2.44

In the table, nivo, pemb, cemi, atez, avel, durv, ipil, poly1, poly2, and poly3, represent nivolumab, pembrolizumab, cemiplimab, atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab+ipilimumab+ pembrolizumab, nivolumab+ipilimumab, and ipilimumab+pembrolizumab, respectively. Bold values indicate the signals with statistical significance.